SOLID TUMOR

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 parti…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This study tests a new drug called ASP3082 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two parts: first, finding a safe dose of ASP3082 alone or with another drug; second, testing it with other cancer treatments. Up to …

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This study tests a new drug called GDC-7035, designed to target cancers with a specific genetic change called KRAS G12D. The trial includes about 410 adults with advanced solid tumors that have not responded to other treatments. Researchers will give the drug alone or with other …

This early-phase trial tests a new drug called SI-B036, a bispecific antibody, in 31 adults with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the drug by IV every 3 we…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This early-stage trial tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…

This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 57…

This phase II trial is testing the drug selinexor in people with Wilms tumor, rhabdoid tumor, MPNST, or other solid tumors that have returned or not responded to treatment. Selinexor works by blocking a protein called XPO1, which is often overactive in these cancers. The study ai…

This early-stage trial tests a combination of low dose radiotherapy, focused radiation (SBRT), and the immunotherapy drug tislelizumab in people with large solid tumors that have not responded to standard treatments. The study aims to see if this approach is safe and tolerable. A…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This early-phase trial is testing whether a specially designed bacteria, CMTS1215, can safely shrink solid tumors. About 20 adults with advanced solid tumors who have no other treatment options will receive the bacteria directly into their tumor or through a vein. The main goals …

This study tests a new drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, testing how well the drug works alone or with chemotherapy in patients whose tumors have…

This early-phase study tests a new drug called DR30206 in about 216 adults with advanced or metastatic solid tumors who have no other treatment options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive t…

This phase 2 trial is testing a drug called TL118 in 60 adults with advanced solid tumors that have a specific genetic change called an NTRK gene fusion. The drug is taken by mouth and aims to shrink tumors or stop them from growing. The study is currently recruiting participants…

This early-stage trial is testing a new oral drug called JBZ-001 in 25 adults with advanced solid tumors or certain blood cancers (like lymphoma) that have not responded to standard treatments. The drug works by blocking a protein cancer cells need to grow. The main goals are to …

This phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see…

This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tu…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This study tests a drug called 177Lu-FAP-2286, which delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like pancreatic, lung, or breast cancer) that have a specific protein called FAP. The trial has two parts: Phase 1 finds the safest dose,…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This early-phase study tests a new drug called BL-M08D1 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. About 22 adults will take part in th…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This study tests an experimental drug called PRL3-zumab in 52 adults with advanced solid tumors. The drug is given by IV every two weeks. Researchers want to see if it can slow cancer growth and how safe it is. Participants must have had no more than three prior treatments and be…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

This early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose and check how well the drug shrinks tumors. About 282 participants will take part across multiple ce…

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This phase 2 trial is testing Envafolimab, an immunotherapy drug given as a shot, in 126 adults with advanced solid tumors that have not responded to standard treatments. The study aims to see if patients with a high number of tumor mutations respond better than those with fewer …

This phase 2 trial is testing an immunotherapy drug called KN035, given as a shot under the skin, for people with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The study includes 200 participants with colorectal cancer or other solid tumors who have a…

This study tests a drug called trilaciclib to protect bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe drops in blood cells, which can be dangerous and delay treatment. Researchers will build a model to predict who benefits most from th…

This study tests a new treatment called Enhanced ALPP CAR-T cells for people with advanced solid tumors that have not responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer cells that hav…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This study tests a new drug called SHR-9839 combined with other cancer treatments in people with advanced solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 70 adults aged 18 to 70 with measurable tumors and good perfo…

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in 100 adults with solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. Participants must be 18-75, in good general health, and have a life e…

This study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…

This study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how wel…

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …

This early-phase trial is testing a new drug called HY0001a in 261 people with advanced solid tumors who have no other treatment options. The study aims to find a safe dose and see if the drug can shrink tumors. It is currently recruiting participants.

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests a new drug called JK06, designed to seek out and attack cancer cells while sparing healthy ones. It is for adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug can shrin…

This study tests a new oral drug called JYP0015 in people with advanced solid tumors (such as pancreatic, lung, or colorectal cancer) that have a RAS mutation. The drug aims to block the activity of the mutated RAS protein, which drives cancer growth. The trial will enroll 210 pa…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if the drug shrinks tumors. Some participants with lymphoma will also receive the drug combined with rituximab. The st…

This early-phase study tests the safety of combining an experimental drug called NEROFE with a standard chemotherapy, doxorubicin, in people with advanced solid tumors that have a KRAS mutation and express ST2. The trial aims to find the best dose and schedule for the combination…

This phase 2 trial tests whether a year-long maintenance regimen of sirolimus (rapamycin) plus low-dose oral chemotherapy and celecoxib can improve 2-year survival without cancer progression in children with high-risk solid tumors. About 55 children and young adults (ages 1–30) w…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This early-phase study tests a new drug called BL-M24D1 in 33 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and get a first look at whether the drug shrinks tumors. Participants receive the d…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to help the immune system attack cancer, followed by a…

This study tests two drugs, AL8326 and toripalimab, together in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors. About 228 adults will take part in this early-phase tr…

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with Ewing sarcoma that has returned or not responded to prior treatments. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 60 participants w…

This early-phase study tests a new drug called IBI3026 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and check for side effects. About 300 participants will take part across multiple centers.

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment involves two injections given directly into the tumor, one after the other. The goal is to find a safe dose and see if it can shrink tumors or slow …

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This early-phase trial is testing an experimental drug called TH9619 in about 43 adults with advanced solid tumors, including colorectal, head and neck, lung, and gastric cancers. The main goal is to check the drug's safety and find the right dose. Participants must have already …

This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.

This early-phase trial is testing an experimental oral drug called OCT-598 in 51 adults with advanced solid tumors, including breast, lung, and prostate cancers. The study aims to find the safest dose and see if the drug works alone or with standard chemotherapy. It is too early …

This early-phase study tests a new drug called GNC-077 in 20 adults with advanced breast cancer or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the drug by injection, and r…

This early-stage trial is testing a new drug called GNC-077, a multi-specific antibody, in 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see how the body processes…

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumo…

This early study tests a new cell therapy called GK01, made from a patient's own immune cells, for advanced solid tumors. Fifteen participants will receive GK01 alone or with chemotherapy after surgery. The main goal is to check safety, not yet to prove it works.

This early-stage study tests a new drug called SHR-A1811(sc) given as a shot under the skin for people with solid tumors. The main goals are to see how the drug moves through the body, check for side effects, and get an early look at whether it helps shrink tumors. About 107 adul…

This early-stage trial tests a new drug called CUSP06 for people with ovarian cancer that has stopped responding to platinum chemotherapy, as well as other advanced solid tumors. CUSP06 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells t…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…

This study tests a tablet called PRaG-1 (made from cordycepin, a mushroom extract) in people who had solid tumors and now have low CD8+ immune cells after finishing radiation or chemotherapy at least six months ago. About 127 participants will take the tablet for two weeks, and t…

This early-phase study tests a new drug called BL-M24D1 in people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 16 adults aged 18 to 75 will ta…

This early-phase study tests a modified virus called VRT106, which is injected directly into tumors to kill cancer cells. It involves 30 adults with advanced solid tumors that haven't responded to standard treatments. The main goal is to check safety and find the best dose, while…

This study tests a new drug called HYP-6589, alone or with other cancer drugs, in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and shrinks tumors. About 115 adults aged 18–80 with certain genetic marker…

This study tests a new drug called SHR-7367 combined with other cancer treatments for people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 100 adults aged 18 to 75 with measurable tumors and good organ function…

This study tests a new drug called HRS-4508 in people with advanced non-small cell lung cancer that has not responded to or cannot tolerate standard treatments. About 120 participants will take the drug as a tablet. Researchers will check how safe it is and whether it shrinks tum…

This early-phase study tests a new drug called PT0253 in about 115 adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants must have …

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the drug combination, and researchers will measure how many achieve a…

This early-phase trial is testing a new approach called Peptide Alarm Therapy (PAT) for people with advanced solid tumors that have not responded to at least one prior treatment, including immunotherapy. PAT is injected directly into a tumor along with a standard PD-1 inhibitor d…

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is.…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-phase trial is testing an experimental drug called BL-M24D1 in 33 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tu…

This early-stage trial is testing an experimental drug called SB17170 in about 50 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking for signs that the drug might …

This study tests a new radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target tumors using tiny particles. The main goals are to check safety, find the right dose, and see if it can s…

This early-stage study is testing a new drug called DCR-PDL1 in about 32 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and how the body processes it, not to cure the cancer. Participants will receive …

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This study tests whether a combination of two drugs, VS-6766 and defactinib, can shrink or control certain gynecological cancers that have come back. It includes women with endometrioid, ovarian, or cervical cancers that have specific gene changes (RAS, BRAF, or NF1). The goal is…

This expanded access program provides nogapendekin-alfa inbakicept (NAI) to adults with solid tumors who have low lymphocyte counts caused by prior cancer treatments like chemotherapy, immunotherapy, or radiation. The goal is to reverse and maintain healthy lymphocyte levels. It …

This study is testing whether umbilical cord blood stem cells from unrelated donors can safely and effectively restore blood cell production in people with serious conditions like leukemia, immune deficiencies, and inherited blood disorders. The main goal is to see how quickly th…

This early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). …

This early-phase study tests a new drug called GNC-039 in people with advanced solid tumors, including a type of brain cancer called glioma, that have come back or spread. The main goals are to check the drug's safety, find the best dose, and see if it can help control the diseas…

This early-phase study tests a new drug called BL-B01D1 in 36 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of tumor shrinkage. Participants will be closely…

This early-stage trial is testing an experimental drug called BB-1709 in 300 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and look for early signs that it might shrink tumors. …

This study tests an experimental drug called BL-B01D1 in people with advanced gynecological cancers or other solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 38 adults aged 18 to 75 wi…

This Phase II trial is testing a drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The study aims to find the best dose and see how well the drug shrinks tumors, while also monitoring safety and si…

This study tests a new drug called IPG1094 in 60 people with advanced solid tumors that cannot be removed by surgery. The drug works by blocking a protein called MIF, which may help slow cancer growth. The trial has two parts: first, finding the safest dose, then seeing if the dr…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that…

This study tests a drug called efbemalenograstim alfa to prevent febrile neutropenia—a serious infection risk—in people with solid tumors undergoing chemotherapy. About 1,076 participants will receive the injection either as a first-time prevention or after a prior low white bloo…

This study tests two AI platforms to personalize cancer treatment for people with solid tumors like gastrointestinal or breast cancer. First, a platform called QPOP analyzes a patient's tumor sample to find the best drug combination. Then, another AI called CURATE.AI adjusts the …

This early-phase study tests a new drug called BL-B16D1 in about 21 adults with recurrent or metastatic head and neck squamous cell carcinoma or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, a…

This early-phase study tests a new drug called BL-M14D1 in 22 adults with advanced small cell lung cancer, neuroendocrine tumors, or other solid cancers that have not responded to standard treatments. The drug is given by IV every 3 weeks. The main goals are to check safety, find…

This early-phase study tests a new drug called BL-M17D1 in 20 people with advanced HER2-positive gastrointestinal cancers (like stomach, pancreas, or colon cancer) or other solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether the …

This early-stage trial is testing a personalized vaccine made from a patient's own tumor tissue. The goal is to see if it is safe and can help the immune system recognize and attack advanced solid cancers. About 30 adults with advanced solid tumors who have already tried other tr…

This early-stage trial is testing a new drug called BL-B16D1 in 21 people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and get …

This early-phase study tests an experimental drug called BL-B16D1 in 21 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and get a first look at wh…

This early-stage trial tests OBT076, a drug that combines an antibody with a chemotherapy agent to target and kill cancer cells that have a specific protein called CD205. The study includes up to 200 adults with advanced solid tumors that have not responded to standard treatments…

This study tests two experimental drugs, LB1410 and LB4330, given together to people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find safe doses and to see if the combination can shrink tumors or slow their growth…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…

This early-stage trial is testing whether an oral probiotic called R-5780 is safe and tolerable when taken alongside a standard PD-1 checkpoint inhibitor in people with advanced solid tumors (like melanoma or certain skin cancers). About 33 adults whose cancer has not responded t…

This early-phase trial is testing a new drug called SON-DP in 96 adults with advanced solid tumors, specifically liver and gastric cancers. The main goals are to check the drug's safety, find the right dose, and see if it can control the disease. Participants receive SON-DP throu…

This study tests an experimental oral drug called ICP-723 in people with advanced solid tumors that cannot be removed by surgery. The trial includes both adults and adolescents (ages 12 and up). The main goals are to check the drug's safety, find the best dose, and see if it can …

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This study tests a new imaging probe called 89Zr-s-C1 that attaches to a protein (MUC18) found on some solid tumors. The goal is to see if this PET/CT scan can find tumors that standard scans miss. About 20 adults with newly diagnosed or recurring solid tumors (like melanoma or s…

This study tests a new radioactive tracer called [68Ga]Ga-THP-PDL1-3 for PET/CT scans in 50 adults with solid tumors. The goal is to see if it can safely and accurately show PD-L1 levels in tumors, which may help doctors personalize cancer treatment. Participants will receive bot…

This early-stage study is testing a new radioactive dye called RT01-89Zr that attaches to a protein found on many solid tumor cells. The goal is to see if it can safely and clearly show tumors on PET/CT scans. About 10 adults with advanced solid tumors will receive the dye and be…

This study tests a new PET scan that uses a special tracer to find a protein called CLDN18.2 on solid tumors. The goal is to see if this scan can help identify which patients might benefit from treatments that target this protein. About 15 adults with solid tumors will receive th…

This study compares whole-body MRI, PET/MR, and PET/CT scans to see which is best at finding tumors in children and young adults with solid tumors, lymphoma, or osteosarcoma. Researchers will check how many tumors each scan detects and measure their metabolic activity. The goal i…

This study tests a special PET scan that uses a radioactive tracer called 68Ga-FAPI to see inflammation in people with Sjögren's syndrome, an autoimmune disease that causes dryness. Researchers will compare the scan results with standard blood tests and also look at scans from ca…

This study tests whether taking mecobalamin (a form of vitamin B12) can prevent or reduce nerve damage caused by taxane chemotherapy. About 326 adults with various solid tumors will take mecobalamin tablets or receive no preventive treatment during their chemo. The goal is to see…

This study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prev…

This study tests whether a topical oil made from aconite can prevent or reduce nerve damage (polyneuropathy) caused by chemotherapy in cancer patients. About 350 adults with solid tumors receiving taxane or platinum chemotherapy will apply the oil or a placebo to their skin twice…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests four different approaches—behavioral therapy, physical therapy, medication changes, and buprenorphine rotation—to help cancer survivors reduce their opioid use while keeping pain under control. It involves 294 veterans who have finished cancer treatment but still…

This study tests whether a special cooling cap can prevent hair loss in children receiving chemotherapy for non-cancerous conditions or solid tumors. The cap is worn before, during, and after chemo to keep the scalp cool. Researchers want to see if it is safe and tolerable for 40…

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …

This study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…

This study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…

This early-stage trial tests AV-380, an antibody that blocks a protein linked to cancer-related weight loss (cachexia). About 30 adults with advanced solid tumors and high GDF-15 levels will receive AV-380 alongside their standard chemotherapy. The main goal is to check safety an…

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This study adapts a counseling program called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. The goal is to improve quality of life and spiritual well-being by addressing the unique challenges this community faces. Researchers will test the program…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study creates a registry for children, teens, and young adults (ages 1 month to 39 years) diagnosed with very rare solid tumors (fewer than 2 cases per million people per year). Researchers will collect medical records, tumor samples, and patient questionnaires to better und…

This study is collecting medical information and biological samples from up to 10,000 people with rare solid tumors, their relatives, and those with genetic mutations that raise cancer risk. Researchers hope to learn how these tumors develop and change over time. The goal is to i…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study follows 100 children and young adults who received CAR T cell therapy to understand short- and long-term side effects like infections, slow blood cell recovery, and nerve problems. Researchers will check participants at 3, 6, 12, and 24 months after treatment. The goal…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study tests if a dye called Indocyanine Green (ICG) can help surgeons find lymph nodes that may contain cancer in children with solid tumors in the belly. About 25 children under 21 with Wilms tumor or a type of muscle cancer will get the dye during surgery. The goal is to s…

This study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…

This study follows 2,000 people who have had ovarian or other solid cancers to learn why some later develop blood cancers like leukemia. Researchers will look at genetic changes in blood cells and treatment history to identify risk factors. No new treatments are being tested—the …

This study is looking at how cancer genetic testing works in people from different ethnic backgrounds. Researchers will collect blood samples and genetic information from 1,800 adults with various solid tumors. The goal is to find cancer-related gene mutations and see if current …

This study is collecting information from 1,000 people with solid tumors who receive chemotherapy through a special catheter called RenovoCath, which delivers drugs directly to the tumor site. Researchers are tracking safety, side effects, and survival over time. The goal is to l…

This study is collecting medical data and biological samples from 15,000 people receiving radiation therapy for solid tumors or blood cancers. Researchers aim to understand how radiation affects quality of life, side effects, and survival. The goal is to learn from real-world out…

This study is creating a detailed database of 651 adults with solid tumors who are starting immunotherapy. Researchers will collect medical and lab information over 5 years to see how well these treatments work in everyday practice. The goal is to learn more about outcomes like s…

This study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…

This research study collects blood and tissue samples from 20,000 people with suspected solid tumors. The samples are stored in a repository for scientists to study later. The goal is to advance our understanding of cancer, not to test a new treatment.

This study collects blood samples from 1,500 adults, including cancer patients, healthy volunteers, and COVID-19 donors. Researchers aim to develop a device that can grow, select, and test immune cells (T cells) from the blood. The goal is to see if these cells can be trained to …

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning earlier than standard scans. About 100 people with different solid tumors will give blood samples after treatment. The goal is to see if early detection can lead to better treatm…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…

This study follows 940 adult cancer patients starting immunotherapy to understand why some develop immune-related side effects, especially those affecting the brain and nerves. Researchers will collect blood samples and health data over time to find early warning signs. The goal …

This study compares a continuous heart-monitoring patch with standard electrocardiograms (ECGs) in 60 adults receiving cancer drugs that can cause dangerous heart rhythm changes. The goal is to see if the patch detects problems more accurately and consistently. Participants will …

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

This study is testing whether cancer patients undergoing chemotherapy can use an iPhone app and Apple Watch to report symptoms from home. Researchers will enroll 100 adults with solid tumors or blood cancers to see if they can consistently use the technology. The goal is to learn…

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study explores whether a liquid biopsy (a blood test) can find genetic changes in tumors to guide personalized cancer treatment. Researchers will enroll 150 adults with solid tumors to see if these tests can help doctors pick better therapies and monitor response. The goal i…

This study aims to collect tissue and blood samples from 3,000 adults with solid tumors to learn why cancers spread and become resistant to treatments. Researchers will use advanced lab tests to find molecular defects that drive cancer growth. The goal is to use this knowledge to…

This study looks at how cancer treatment impacts the work life and overall well-being of 400 men, ages 21 to 70, who have been newly diagnosed with solid tumors like colorectal, lung, or head and neck cancer. Participants will fill out questionnaires about their work hours, finan…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study is testing a new predictive model that analyzes tumor samples to forecast whether a patient with melanoma or other skin cancers will respond to immunotherapy. Researchers will compare the model's predictions with actual patient outcomes over six months. The goal is to …

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…